Biotek-snakken — Februar 2025
-
Genovis Q4 2024: Solid but softer than we estimated
(Redeye Research Update 2025-02-17)
-
Når man læser Photocures Q4 og høre deres livepræsentation så får jeg det indtryk at der er lagt i ovnen til flere års solid vækst. Der ud over er der to meget vigtige begivenheder, nedklassifisering i USA og godkendelse i kina som begge forventes i år. Ud over milestones på over 100 mil NOK fra Kina kan nedklassefiseringen USA sparke endnu mere gang i USA salget. Jeg har lidt svært ved at forstå kursreaktionen efter Q4 men så er der jo tid til at samle lidt flere aktier op (-:
-
Medix has resubmitted tesofensine application to COFEPRIS
Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces that its partner Medix has resubmitted the tesofensine application dossier to COFEPRIS, as referenced in Saniona’s press release dated February 10.
"I congratulate the Medix team on this significant achievement. Following feedback from COFEPRIS, they have updated and resubmitted the complete tesofensine dossier - approximately 20,000 pages - addressing al
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind